View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOrapi 過去の業績過去 基準チェック /06Orapiの収益は年間平均-76.2%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間4.4% 2.7%割合で 減少しています。主要情報-76.17%収益成長率-72.91%EPS成長率Chemicals 業界の成長12.41%収益成長率-2.69%株主資本利益率-90.53%ネット・マージン-11.77%前回の決算情報30 Jun 2024最近の業績更新Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.すべての更新を表示Recent updatesNew Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.収支内訳Orapi の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:O4P 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 24226-2790031 Mar 24228-2388031 Dec 23229-1987030 Jun 23228-787031 Mar 23227-388031 Dec 22227189030 Jun 22228093031 Mar 22227093031 Dec 21227093030 Sep 21236297030 Jun 212453101031 Mar 212566103031 Dec 202689105030 Sep 202605101030 Jun 20252097031 Mar 20246-197031 Dec 19240-397030 Sep 192470101030 Jun 192543105031 Mar 192550108031 Dec 18256-4110030 Sep 18251-4110030 Jun 18247-4109031 Mar 18245-3109031 Dec 17244-2109030 Sep 17243-1109030 Jun 172420109031 Mar 17245-1111031 Dec 16248-1113030 Sep 16255-3116030 Jun 16263-4119031 Mar 16270-5122031 Dec 15277-6126030 Sep 15265-3121030 Jun 15252-1116031 Mar 152360110031 Dec 142202105030 Sep 142202105030 Jun 142212105031 Mar 142163103031 Dec 1321131010質の高い収益: O4Pは現在利益が出ていません。利益率の向上: O4Pは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: O4Pは利益が出ておらず、過去 5 年間で損失は年間76.2%の割合で増加しています。成長の加速: O4Pの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: O4Pは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -13.5% ) と比較することは困難です。株主資本利益率高いROE: O4Pは現在利益が出ていないため、自己資本利益率 ( -90.53% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/22 13:00終値2024/12/11 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Orapi SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stephanie LefebvreGilbert Dupont
Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.
Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.
New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).
Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).
New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.
Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.
Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.
Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.
Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.